RecruitingNot ApplicableNCT05652621

Efficacy of Probiotics in Patients With IBD

Clinical Efficacy and Mechanism of Probiotics in the Adjuvant Treatment of Ulcerative Colitis and Irritable Bowel Syndrome


Sponsor

The First Affiliated Hospital of Xinxiang Medical College

Enrollment

200 participants

Start Date

Jul 31, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This research group plans to take patients with mild to moderate UC and diarrhea IBS diagnosed in the First Affiliated Hospital of Xinxiang Medical College as examples, and divide them into UC group and IBS group; Each group was randomly divided into two groups, namely, conventional treatment+probiotics group and conventional treatment+probiotics placebo group.Starting from the intervention of probiotics on intestinal flora to alleviate intestinal injury caused by UC and IBS patients, the indicators of intestinal flora, serum inflammatory factors, metabolites in vivo, intestinal barrier-related protein expression, and fecal short-chain fatty acid level were detected to explore the clinical efficacy, intestinal protective effect and mechanism of probiotics in adjuvant treatment of UC and IBS patients.To provide new methods and new ideas for refractory UC and IBS, so as to improve the cure rate of UC and IBS, reduce the recurrence rate, relieve the physical and mental pain and economic burden of patients, and provide new ideas for the development and utilization of functional probiotics. It also seeks biosafety evidence for the future use of probiotics in antibiotic environment.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

  • Clinical diagnosis of ulcerative colitis
  • Clinical diagnosis of irritable bowel
  • Can swallow probiotic pellets as required

Exclusion Criteria1

  • indeterminate colitis,suspected IBD

Interventions

DIETARY_SUPPLEMENTprobiotics

Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5)


Locations(1)

The First Affiliated Hospital of Xinxiang Medical College

Xinxiang, Henan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05652621


Related Trials